RecruitingNCT06466629

The Optimal Timing of Vaccination in Pregnancy

The Optimal Timing of Vaccination in Pregnancy: a Multi-dimensional Mechanistic Approach to Measure Immune Responses in Pregnant Women


Sponsor

Elke Leuridan, MD, PhD

Enrollment

96 participants

Start Date

Jul 1, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

The central aim of this study is to investigate the optimal timing of vaccination in pregnant women. Therefore, pregnant women will be vaccinated against pertussis at different timepoints and blood and breast milk samples will be taken at several timepoints. The main objectives are to assess the impact of timing on humoral and cellular immune responses in pregnant women, on antibody characteristics transferred across the placenta and on transplacental transport efficiency. The impact of maternal pertussis vaccination and timing of maternal pertussis vaccination on breastmilk antibody composition will also be investigated, as well as the impact of vaccination during pregnancy on the mucosal uptake of breastmilk IgA antibodies by the infant respiratory and gastrointestinal tract.


Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria4

  • Ability to provide informed consent.
  • Willing to be vaccinated with a Tdap vaccine during pregnancy.
  • Intend to be available for follow-up visits and phone call access until 6 months postpartum.
  • Influenza and COVID-19 vaccination during pregnancy (as per Belgian recommendations) is allowed.

Exclusion Criteria7

  • Vaccinated with an aP containing vaccine during the last 5 years
  • Significant mental illness (e.g. schizophrenia, psychosis, major depression)
  • Serious underlying immunological condition (e.g. immunosuppressive disease or therapy, human immunodeficiency virus (HIV) infection…).
  • Systemic treatment with immune suppressive medication, including chronic steroid use of > 10 mg prednisone or equivalent.
  • Anything in the opinion of the investigator that would prevent volunteers from completing the study or put the volunteer at risk.
  • Previous severe reaction to any vaccine
  • High risk for serious obstetrical complications.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALTriaxis, Sanofi Pasteur

tetanus, diphtheria, acellular pertussis (aP) (Tdap) vaccine


Locations(1)

Vaccinopolis

Edegem, Antwerp, Belgium

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06466629


Related Trials